Upfront CLL treatment with single agent obinutuzumab.

e18039 Background: Obinutuzumab is a type 2 anti-CD20 monoclonal antibody approved in combination with chlorambucil for the initial treatment of CLL. In a randomized study, treatment with chlorambu...